K
Kerri St. Denis
Researcher at Ragon Institute of MGH, MIT and Harvard
Publications - 20
Citations - 1877
Kerri St. Denis is an academic researcher from Ragon Institute of MGH, MIT and Harvard. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 7, co-authored 18 publications receiving 599 citations. Previous affiliations of Kerri St. Denis include Harvard University.
Papers
More filters
Journal ArticleDOI
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
Wilfredo F. Garcia-Beltran,Wilfredo F. Garcia-Beltran,Evan C. Lam,Kerri St. Denis,Adam Nitido,Zeidy H. Garcia,Blake M. Hauser,Jared Feldman,Maia N. Pavlovic,David Gregory,Mark C. Poznansky,Alex Sigal,Alex Sigal,Aaron G. Schmidt,A. John Iafrate,Vivek Naranbhai,Vivek Naranbhai,Alejandro B. Balazs +17 more
TL;DR: In this article, the authors evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2.
Posted ContentDOI
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
Wilfredo F. Garcia-Beltran,Wilfredo F. Garcia-Beltran,Evan C. Lam,Kerri St. Denis,Adam Nitido,Zeidy H. Garcia,Blake M. Hauser,Jared Feldman,Maia N. Pavlovic,David Gregory,Mark C. Poznansky,Alex Sigal,Alex Sigal,Aaron G. Schmidt,A. John Iafrate,Vivek Naranbhai,Alejandro B. Balazs +16 more
TL;DR: In this article, the authors evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against 10 globally circulating strains of SARS-CoV-2.
Journal ArticleDOI
Erratum: Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity (Cell (2021) 184(9) (2372–2383.e9), (S0092867421002981), (10.1016/j.cell.2021.03.013))
Wilfredo F. Garcia-Beltran,Wilfredo F. Garcia-Beltran,Evan C. Lam,Kerri St. Denis,Adam Nitido,Zeidy H. Garcia,Blake M. Hauser,Jared Feldman,Maia N. Pavlovic,David Gregory,Mark C. Poznansky,Alex Sigal,Aaron G. Schmidt,Aaron G. Schmidt,A. John Iafrate,Vivek Naranbhai,Alejandro B. Balazs +16 more
Journal ArticleDOI
Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents.
David H. Canaday,David H. Canaday,Lenore L. Carias,Oladayo A. Oyebanji,Debbie Keresztesy,Dennis Wilk,Mike C. Payne,Htin Aung,Kerri St. Denis,Evan C. Lam,Christopher F. Rowley,Sarah D. Berry,Cheryl M. Cameron,Mark J. Cameron,Brigid Wilson,Alejandro B. Balazs,Stefan Gravenstein,Stefan Gravenstein,Christopher L. King +18 more
TL;DR: After BNT162b2 mRNA vaccination, antibody levels to spike, receptor binding domain (RBD) and virus neutralization were examined in 149 nursing home (NH) residents and 110 health care worker controls.
Journal ArticleDOI
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.
Vivek Naranbhai,Vivek Naranbhai,Claire A. Pernat,Alexander Gavralidis,Alexander Gavralidis,Kerri St. Denis,Evan C. Lam,Laura Spring,Steven J. Isakoff,Jocelyn R. Farmer,Leyre Zubiri,Gabriela S. Hobbs,Joan How,Joan How,Andrew M. Brunner,Amir T. Fathi,Jennifer L Peterson,Mustafa Sakhi,Grace Hambelton,Elyssa Denault,Lindsey Mortensen,Lailoo A Perriello,Marissa N Bruno,Brittany Y Bertaux,Aleigha Lawless,Monica A Jackson,Elizabeth Niehoff,Caroline Barabell,Christian N Nambu,Erika Nakajima,Trenton Reinicke,C. Bowes,Cristhian J Berrios-Mairena,Onosereme Ofoman,Grace Kirkpatrick,Julia Thierauf,Kerry L. Reynolds,Henning Willers,Wilfredo-Garcia Beltran,Wilfredo-Garcia Beltran,Anand S. Dighe,Rebecca R. Saff,Kimberly G. Blumenthal,Ryan J. Sullivan,Yi-Bin Chen,Arthur Y. Kim,Aditya Bardia,Alejandro B. Balazs,A. John Iafrate,Justin F. Gainor +49 more
TL;DR: This article performed a prospective cohort study of adults with solid-organ or hematologic cancers to evaluate anti-SARS-CoV-2 immunoglobulin A/M/G spike antibodies, neutralization, and reactogenicity ≥ 7 days following two doses of mRNA-1273, BNT162b2, or one dose of Ad26.COV2.